ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma (CTCL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01579318
Recruitment Status : Terminated (Due to company resource constraints)
First Posted : April 17, 2012
Results First Posted : January 3, 2018
Last Update Posted : January 3, 2018
Sponsor:
Information provided by (Responsible Party):
OncoSec Medical Incorporated

Brief Summary:

A single arm, open label, multi-center, phase 2 study to assess the safety and anti-tumor activity of ImmunoPulse IL-12® in participants with stage IB to IIIB mycosis fungoides. ImmunPulseIL12® is the combination of intrtumoral interleukin-12 gene (also known as tavokinogene telseplasmid [tavo]) and in vivo electroporation-mediated plasmid deoxyribonucleic acid [DNA] vaccine therapy (tavo-EP) administered using the OncoSec Medical System (OMS).

All participants may receive up to four cycles of treatment consisting of three treatment days, Days 1, 5 and 8, in a 12-week cycle as per Protocol version 6 (see Limitations and Caveats section of this record for protocol version information). Patients will receive intra-tumoral injection of tavo at a concentration of 1.0 mg/mL (maximum volume of 1 mL/day distributed over 2-4 lesions), followed immediately by electrical discharge around the tumor site resulting in electroporation of plasmid deoxyribonucleic acid (DNA) into tumor cells.


Condition or disease Intervention/treatment Phase
Cutaneous T Cell Lymphomas (CTCL) Mycosis Fungoides (MF) Biological: Tavokinogene Telseplasmid (tavo) Device: OncoSec Medical System (OMS) Phase 2

Detailed Description:
This is a single arm, open label, multi-center phase 2 study to assess the safety and anti-tumor activity of intratumoral tavo electroporation in participants with stage IB to IIIB mycosis fungoides. All participants received up to four cycles of treatment consisting of three treatment days, Days 1, 5 and 8, in a 12-week cycle. Patients will receive intra-tumoral injection of tavo at a concentration of 1.0 mg/mL (maximum volume of 1 mL/day distributed over 2-4 lesions), followed immediately by electrical discharge around the tumor site resulting in electroporation of plasmid deoxyribonucleic acid (DNA) into tumor cells. Prior to the first cycle of treatment, the investigator will select at least one lesion, or affected area in erythrodermic patients, to be left untreated for the duration of the study to allow for clinical observation of an untreated site. Participants will be followed for safety and clinical evaluation every 4 weeks. Quality of Life will be assessed using the Skindex29, Functional Assessment of Cancer Therapy - General (FACT-G) and Visual Analog Scale for Pruritus (VAS-P) instruments. Survival follow up will occur at 3-month intervals over 2 years following end of study.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter Phase II Trial of Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma
Actual Study Start Date : June 8, 2012
Actual Primary Completion Date : June 3, 2014
Actual Study Completion Date : June 3, 2014


Arm Intervention/treatment
Experimental: Treatment
Participants received up to 4 cycles of treatment (3 daily treatments on Days 1, 5 and 8, in a 12-week cycle) of intratumoral injection(s) of tavo at a concentration of 1.0 mg/mL (maximum volume of 1 mL/day distributed over 2-4 lesions), followed immediately by electrical discharge around the tumor site resulting in electroporation of plasmid deoxyribonucleic acid (DNA) into tumor cells.
Biological: Tavokinogene Telseplasmid (tavo)
Patients received intratumoral injection(s) of tavo.
Other Names:
  • interleukin-12 gene
  • IL-12 gene
  • pIL-12
  • plasmid DNA encoding human interleukin-12
  • plasmid IL-12
Device: OncoSec Medical System (OMS)
Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulseswere administered to each tumor lesion at the approximate point of tavo injection.
Other Name: MedPulser



Primary Outcome Measures :
  1. Objective Response Rate Assessed by Modified Severity Weighted Assessment Tool (mSWAT) Score in the Skin [ Time Frame: Every 28 days for the first 24-weeks of treatment ]
    ORR is defined as the percentage of participants that achieved a complete response (CR) or partial response (PR) as assessed by mSWAT score. The mSWAT defines 3 lesion types and assigns each a weighing factor: patch (no induration or significant elevation)=1; plaque (induration, crusting, ulceration or poikiloderma)=2; tumor (solid or nodular ≥ 1 cm in diameter with evidence of deep infiltration and/or vertical growth)=4. Lesions are assessed by body surface area (BSA) where palm + fingers = approximately 1% BSA in each of 12 areas (head, neck, anterior trunk, arms, forearms, hands, posterior trunk, buttocks, thighs, legs, feet, groin), and the sum of each area of BSA is multiplied by its weighing factor. An overall sum of each subtotal represents the mSWAT score (0=no lesions; 400=lesions covering all areas). CR=100% clearance of skin lesions; PR= 50%-99% clearance of skin disease from baseline without new tumors ( ≥1.0 cm in diameter) in patients with T1, T2 or T4 only skin disease.

  2. Objective Response Rate Assessed by Modified Severity Weighted Assessment Tool (mSWAT) Composite Global Score [ Time Frame: Every 28 days for the first 24-weeks of treatment ]
    ORR is defined as the percentage of participants that achieved a complete response (CR) or partial response (PR) as assessed by mSWAT Composite Global Score. This assessment evaluated skin, lymph node, blood and visceral involvement. The response generated in each category was used to determine the Global ORR: CR=complete disappearance of all clinical evidence of disease or, no involvement of disease at baseline through time of response evaluation (NI); PR=regression of measurable disease as follows: 100% clearance of skin lesions, all other categories do not have CR/NI and no category has progressive disease (PD) -OR- 50%-99% clearance of skin disease from baseline without new tumors ( ≥1.0 cm in diameter) in patients with T1, T2 or T4 only skin disease, and if any other category was involved at baseline, at least one has CR/PR and no category has PD.


Secondary Outcome Measures :
  1. Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: From the start of study treatment up to 340 days ]
    An AE was any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product, medical treatment or procedure and which did not necessarily have to have had a causal relationship with this treatment. An adverse event could have, therefore, been any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, medical treatment or procedure whether or not considered related to the medicinal product. An SAE was defined an any untoward medical occurrence that at any dosage resulted in one or more of the following: death, A life-threatening adverse event (real risk of dying), inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly, required intervention to prevent permanent impairment of damage.

  2. Duration of Overall Objective Response Assessed by mSWAT Skin Score [ Time Frame: From first documented response until disease progression (Up to 340 days) ]
    Duration of overall objective response (CR or PR) is defined as the number of days from the initial documentation of an objective response to the most current evaluation of that response or to documentation of progression assessed by mSWAT Skin Score: CR=100% clearance of skin lesions; PR= 50%-99% clearance of skin disease from baseline without new tumors ( ≥1.0 cm in diameter) in patients with T1, T2 or T4 only skin disease.

  3. Time to Overall Objective Response Assessed by mSWAT Skin Score [ Time Frame: From start of study treatment until overall objective response (Up to 340 days) ]
    Time to overall objective response (CR or PR) is the number of days from the start of therapy to the first documentation of objective response assessed by mSWAT Skin Score: CR=100% clearance of skin lesions; PR= 50%-99% clearance of skin disease from baseline without new tumors ( ≥1.0 cm in diameter) in patients with T1, T2 or T4 only skin disease.

  4. Quality of Life (QoL) [ Time Frame: Every 28 days for up to 340 days ]
    Participants were to complete the following QoL assessments prior to clinical evaluations every 4 weeks: Skindex29, FACT-G (Functional Assessment of Cancer Therapy -General) and VAS-P (Visual Analog for Pruritus) questionnaires.


Other Outcome Measures:
  1. Immunologic Effects of IL-12 Plasmid Electroporation in Tissue [ Time Frame: 2 years ]

    This outcome measure was erroneously entered as secondary but is truly an exploratory endpoint.

    Planned analyses were:

    1. Transcriptional analysis of interferon pathway activation, antigen presentation and processing machinery (APM) upregulation, and immune cell infiltration in tissue at baseline and post-treatment.
    2. Changes in the characterization of local tissue effects, proportion and phenotype, of intratumoral leukocyte subsets post-treatment.
    3. Changes in T cell receptor clonal expansion and persistence of initial clones post- treatment.
    4. Changes in FOXP3 methylation and quantification of regulatory T cells post- treatment.

  2. Immunologic Effects of IL-12 Plasmid Electroporation in Peripheral Blood [ Time Frame: 2 years ]

    This outcome measure was erroneously entered as secondary but is truly an exploratory endpoint.

    Planned analyses were:

    1. Changes in the proportion of circulating regulatory and effector T cells in peripheral blood.
    2. Changes in phenotype of leukocyte subsets and T cell receptor clonal expansion



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  1. Biopsy confirmed mycosis fungoides of stage IB - IIIB;
  2. Participants must have failed or have been intolerant to at least one standard of care therapy;
  3. Participants must have a minimum of one lesion, or affected area in erythrodermic patients (T4/stage III), that meets all following criteria:

    • Accessible for pIL-12 electroporation;
    • Adequate size such that 6-mm biopsy can be collected prior to treatment;
  4. Participants must have one additional lesion, or affected area in erythrodermic patients, that remains untreated for the duration of the study;
  5. Age ≥ 18 years old;
  6. Participants must have Eastern Cooperative Oncology Group (ECOG) performance status 0-2;
  7. Required wash out period of 4 weeks from last dose for the following prior therapies:

    • Topical therapy;
    • Radiotherapy (including photo therapy);
    • Multi-agent chemotherapy;
    • Systemic biological therapy;
    • Histone deacetylase inhibitors (HDAC) inhibitors;
    • Interferon alpha and other investigational therapies;
  8. For women of childbearing potential, negative pregnancy serum test within 14 days to the first study drug administration, and use of birth control from 30 days prior to the first day study drug administration and 30 days following last day study drug administration;
  9. Male participants must be surgically sterile, or must agree to use contraception during the study and at least 30 days following the last day of study drug administration.
  10. Life expectancy of at least 6 months;
  11. The patient must have adequate renal and hepatic function as assessed by standard laboratory criteria within 4 weeks prior to enrollment:

    • Creatinine < 2 x upper limit of normal (ULN);
    • Serum bilirubin within institutional normal limits;
    • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 x ULN;
    • Absolute neutrophil count (ANC) > 1000/mm;
    • Platelet count > 100,000 /mm;
  12. Able to give informed consent and able to follow guidelines given in the study.

Exclusion Criteria

  1. Prior therapy with IL-12 or prior gene therapy;
  2. Prior treatment with Campath (alemtuzumab) within 1 year of enrollment;
  3. Concurrent immunotherapy, chemotherapy, or radiation therapy for duration of patient participation on study;
  4. Concurrent steroid therapy;
  5. Concurrent anticoagulant therapy (acetylsalicylic acid [ASA]≤ 325mg/day allowed);
  6. Evidence of significant active infection (e.g., pneumonia, cellulitis, wound abscess, etc.) at time of study enrollment;
  7. Patients with current evidence of large cell transformation (LCT) with aggressive disease at study entry (patients with a history of LCT are eligible if pathologic evidence at study entry indicates there is no presence of LCT);
  8. Known history of human immunodeficiency virus (HIV), Human T-cell leukemia virus (HTLV) -1/2 infection, hepatitis B or hepatitis C (active, prior treatment, or both);
  9. No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 2 years;
  10. Significant cardiovascular disease (i.e. New York Heart Association [NYHA] class 3 congestive heart failure; myocardial infarction within the past 6 months; unstable angina; coronary angioplasty with the past 6 months; uncontrolled atrial or ventricular cardiac arrhythmias);
  11. Any other medical history, including laboratory results, deemed by the investigator to be likely to interfere with patient's participation in the study, or to interfere with the interpretation of the results;
  12. Participants with electronic pacemakers or defibrillators are excluded from this study as the effect of electroporation on these devices is unknown;
  13. Pregnant and breast-feeding women are excluded from the study as effects on the fetus are unknown and there may be a risk of increased fetal wastage.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01579318


Locations
United States, California
UCSF Helen Diller Comprehensive Cancer Center
San Francisco, California, United States, 94115
Sponsors and Collaborators
OncoSec Medical Incorporated

Responsible Party: OncoSec Medical Incorporated
ClinicalTrials.gov Identifier: NCT01579318     History of Changes
Other Study ID Numbers: OMS-I120
First Posted: April 17, 2012    Key Record Dates
Results First Posted: January 3, 2018
Last Update Posted: January 3, 2018
Last Verified: January 2018

Additional relevant MeSH terms:
Lymphoma
Lymphoma, T-Cell
Mycoses
Mycosis Fungoides
Lymphoma, T-Cell, Cutaneous
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Interleukin-12
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents